Wed Sep 25 08:20:53 UTC 2024: ## Biohaven Stock Receives Positive Analyst Attention, Despite Recent Earnings Miss
**New York, NY** – Biohaven (BHVN), a pharmaceutical company focused on developing therapies for various illnesses, is seeing positive sentiment from analysts despite a recent earnings miss.
Multiple investment firms have reiterated their buy rating on the stock, with several raising their price targets. Leerink Partners increased their target to $60.00, while Piper Sandler boosted theirs to $76.00. Notably, Morgan Stanley initiated coverage on Biohaven with an overweight rating and a $58.00 price target.
This bullish outlook comes despite Biohaven reporting a quarterly earnings per share (EPS) of ($3.64), missing the consensus estimate of ($1.72). However, analysts remain optimistic about the company’s future, anticipating a -8.92 EPS for the current year.
Further contributing to investor confidence, Director John W. Childs recently purchased 28,400 shares of Biohaven stock, demonstrating his belief in the company’s potential.
Institutional investors are also showing interest in the company. Several firms, including Clearbridge Investments LLC, Quarry LP, and Algert Global LLC, increased their holdings in Biohaven during the second quarter.
Biohaven’s pipeline of promising therapies, particularly in the fields of immunology, neuroscience, and oncology, continues to drive investor interest. The company’s flagship products, including Troriluzole, Taldefgrobep Alfa, and BHV-7000, are currently in various stages of clinical trials.
Overall, despite the recent earnings miss, Biohaven’s stock remains attractive to analysts and investors, suggesting a strong belief in its future prospects.
First Piper 